Try our beta test site

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58)

This study has been completed.
Sponsor:
Collaborators:
University of Virginia
National Cancer Institute (NCI)
Oncovir, Inc.
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia
ClinicalTrials.gov Identifier:
NCT01585350
First received: April 24, 2012
Last updated: August 11, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)